1. Introduction
===============

Owing to the epidemiological shift in the 20^th^ century, infectious disease-related death and disability have decreased; however, they have increased rapidly owing to noninfectious diseases including cardiovascular disease (CVD), which have some of the highest mortality and morbidity rates. After the 1930s, mortalities due to CVD exceeded those due to tumors, tuberculosis, and pneumonia. CVD became a leading cause of mortality in developed countries \[[@b1-ad-11-2-419]\]. CVD includes heart and vascular diseases and is a major public health concern and cause of mortality \[[@b2-ad-11-2-419]\]. The prevalence of CVD has increased notwithstanding improvements in treatment and management methods. Age-standardized mortality of CVD has decreased by 14.5% over the past two decades \[[@b3-ad-11-2-419]\]. Nonetheless, with an increase in the incidence of cardiovascular disease and changes in the disease spectrum, the incidence of CVD and CVD-associated mortality are expected to increase worldwide in future decades. Therefore, prevention and treatment of cardiovascular disease is extremely urgent \[[@b4-ad-11-2-419]\]. In CVD, the final and the most prominent phenomenon is cell death caused by harmful stimuli and aging. Mitochondria provide energy for cellular metabolism and are involved in cell death. They participate in cell proliferation, apoptosis, signal transduction, and calcium homeostasis. Hence, the mitochondrial steady state is essential for cellular function \[[@b5-ad-11-2-419]-[@b7-ad-11-2-419]\].

Mitochondria are the most abundant organelles in cardiomyocytes and are very important for the maintenance of normal cell function. Mitophagy is selective autophagy wherein cells eliminate damaged or dysfunctional mitochondria, which is essential for the regulation of mitochondrial homeostasis \[[@b8-ad-11-2-419]-[@b10-ad-11-2-419]\]. Mitophagy was first proposed by Lemasters et al. in 2005. Since then, numerous diseases have been associated with mitophagy \[[@b11-ad-11-2-419]\]. Recent studies revealed that mitophagy contributes to the pathophysiology of CVD. Mitophagy regulates cardiovascular activity through several pathways \[[@b12-ad-11-2-419]-[@b22-ad-11-2-419]\]. The present review discusses mitophagy and its underlying mechanisms, methods to assess mitophagy and its involvements in CVD.

Figure 1.The mechanisms underlying mitophagy. (A) An overview of the mechanisms underlying mitophagy. (B) Step1: Phagophores are formed by the isolated membrane and LC3. Step2: Thereafter, through LC3 adaptors and LC3 receptors, damaged mitochondria can be recognized and form mitophagosomes. The detailed mechanism can be divided into six stages. a. CHDH accumulates on the outer mitochondrial membrane (OMM) and interacts with p62 and binds with LC3. b. PINK1 accumulates on the OMM, phosphorylates Parkin and Mfn2, thus recruiting Parkin to the OMM, and Parkin helps generate ubiquitin chains on the OMM, which can recognize p62 and bind with LC3. c. PINK1 phosphorylates ubiquitin on the OMM and LC3 adapters can bind with it. d. LC3 directly recognizes BNIP3 or Nix through LIR, and phosphorylation of LIR in BNIP3 promotes the interaction between BNIP3 and LC3. e. Dephosphorylation of FUNDC1 restores its ability to interact with LC3 through LIR. f. AMBRA1, Bcl2L13, and cardiophospholipids directly recognize LC3 through LIR. Step3: Mitophagosomes and lysosomes fuse into mitolysosomes.

2. Mitophagy
============

Mitochondria regulate calcium steady state, signal transmission between organelles, and oxidative phosphorylation for ATP biosynthesis. Mitochondrial DNA (mtDNA) is present in the matrix or membrane and does not combine with histones. Therefore, mtDNAs are relatively vulnerable to reactive oxygen species (ROS) and influenced by mutations. Mitochondria are more susceptible to oxidative damage than other organelles \[[@b23-ad-11-2-419]-[@b25-ad-11-2-419]\]. Dysfunctional and damaged mitochondria generate excess ROS, which damage proteins, membrane lipids, nucleic acids, adjacent mitochondria and release proapoptotic proteins into the cytosol, eventually causing cell death \[[@b25-ad-11-2-419]-[@b28-ad-11-2-419]\]. Hence, prompt and appropriate elimination of damaged or aging mitochondria is vital for normal cell growth. This process is executed by mitophagy \[[@b11-ad-11-2-419]\].

Autophagy involves the degradation of the protoplasm by lysosomes, resulting in macrophage-, microphage-, and chaperone-mediated autophagy. Selective autophagy occurs in response to nutrient deficiency, whereas nonspecific autophagy is caused by cell aging or a response to damaged cell components. Mitophagy is a selective autophagy pathway involving the elimination of abnormal mitochondria and maintains mitochondrial homeostasis \[[@b16-ad-11-2-419], [@b29-ad-11-2-419]-[@b32-ad-11-2-419]\].

2.1 Mitophagy and related factors
---------------------------------

Mitophagy is divided into three steps: formation of phagocytic vesicles, recognition of damaged mitochondrial components and compartmentation into mitochondrial phagocytic vesicles, and fusion of mitochondrial phagocytic vesicles and lysosomes into mitolysosomes \[[@b16-ad-11-2-419], [@b33-ad-11-2-419], [@b34-ad-11-2-419]\]([Fig. 1](#F1-ad-11-2-419){ref-type="fig"}). The mitophagy pathway was first identified in yeast in 2004. Mitochondrial outer membrane protein autophagy-related gene 32 (Atg32) recruits core autophagy molecules to the mitochondria for selective clearance \[[@b35-ad-11-2-419]-[@b37-ad-11-2-419]\]; however, no homologs have been reported in the human genome thus far. The subsequent section summarizes the mechanisms underlying mitophagy in accordance with the three aforementioned stages.

Step 1. Formation of phagocytic vesicles (Phagophores)
------------------------------------------------------

Phagocytic vesicles are isolated membranous structures in the endoplasmic reticulum (ER) of mammalian cells. The formation of phagocytic vesicles is regulated by an evolutionarily conserved protein (Atg) system \[[@b35-ad-11-2-419], [@b37-ad-11-2-419]-[@b39-ad-11-2-419]\]. Atg6 recruits other Atg proteins to the isolation membrane, thus warranting the Atg5-Atg12 and LC3-phosphatidylethanolamine conjugation systems. Covalent conjugation between Atg12 and Atg5 resembles ubiquitination, wherein Atg12 is initially activated by Atg7, and then transferred to Atg10. Atg12 is then covalently conjugated with Atg5 at a lysine residue and Atg10 is released. Finally, the Atg12-Atg5 complex interacts non-covalently with Atg16, which then initiates the elongation of the membrane by recruiting LC3-phosphatidylethanolamine \[[@b39-ad-11-2-419]\]. LC3 is a surface molecule on phagocytic vesicles. Phagocytic vesicles are formed by combining LC3-I with phosphatidylethanolamine to produce lipid LC3-II \[[@b33-ad-11-2-419], [@b40-ad-11-2-419], [@b41-ad-11-2-419]\].

Step 2. Recognition of damaged mitochondrial components and compartmentation into mitochondrial phagocytic vesicles (Mitophagosomes)
------------------------------------------------------------------------------------------------------------------------------------

Mitophagy is a type of selective organellar autophagy in mammalian cells. Identification of phagocytic vesicles and their combination with damaged mitochondria have received increasing attention in studies on mitophagy \[[@b33-ad-11-2-419], [@b42-ad-11-2-419]\]. Damaged mitochondria are recognized by LC3 adapters or LC3 receptors. First, we address the recognition of impaired mitochondria by LC3 adapters.

### PINK1 and Parkin

In mammalian cells, PINK1/Parkin-mediated mitophagy is the most extensively characterized mitophagic phenomenon thus far \[[@b43-ad-11-2-419]\]. PINK1 is a serine/threonine kinase with an N-terminal mitochondrial targeting signal \[[@b44-ad-11-2-419]\]. In intact mitochondria, PINK1 is recruited to the mitochondria by translational enzymes on the outer mitochondrial membrane (OMM) and the endometrial complex, anchored within the mitochondrial endometrium, and continuously degraded by protease and peptidase. During mitochondrial depolarization, however, translocation of PINK1 across to the inner mitochondrial membrane (IMM) is inhibited. PINK1 is not degraded but aggregates at the outer membrane \[[@b16-ad-11-2-419], [@b42-ad-11-2-419]\].

PINK1 utilizes its own ubiquitin-like domain to function like ubiquitin. Activated PINK1 phosphorylates Parkin (a cytoplasmic E3 ubiquitin ligase) at T175, thus activating Parkin, which in turn aggregates in the OMM. However, activated PINK1 also phosphorylates Mfn2, which can then serve as a Parkin receptor in cardiomyocyte mitochondria. This process also induces Parkin aggregation on the OMM \[[@b43-ad-11-2-419], [@b45-ad-11-2-419]-[@b47-ad-11-2-419]\]. Phospho-parkin helps generate ubiquitin chains on the OMM proteins through polyubiquitination, thus amplifying the signal, and these ubiquitin chains serve as LC3 adapter recognition sites, which bind to LC3 and initiate mitophagy \[[@b48-ad-11-2-419], [@b49-ad-11-2-419]\].

PINK1 may also be recruited in a Parkin-independent manner. PINK1 phosphorylates the mitochondrial ubiquitin on OMM at S65. LC3 adapters such as optineurin and NDP52 recognize the damaged mitochondria and ubiquitin phosphorylated at S65 through the ubiquitin-binding region \[[@b48-ad-11-2-419]\].

### Choline dehydrogenase (CHDH)

CHDH oxidizes choline to betaine aldehyde in the mitochondria. In normal mitochondria, CHDH is unanchored at both the OMM and IMM. In depolarized mitochondria, CHDH accumulates on the OMM and its FAD/NAD-binding domain 1 interacts with the Phox and Bem1 domains in cytoplasmic p62/SQSTM1, thus recruiting p62/SQSTM1 at damaged mitochondria and binding with LC3 \[[@b42-ad-11-2-419], [@b50-ad-11-2-419]\].

In summary, the impaired mitochondrial recognition process mediated by the LC3 adapter is divided into the ubiquitin-associated type (PINK1/Parkin) and the ubiquitin-independent type (CHDH). Five LC3 adapters have been identified including OPTN, p62/SQSTM1, NBR1, NDP52, and TAX1BP, which mediate the recognition and phagocytosis of damaged mitochondria by joining LC3-coated phagocytic vesicles to label damaged mitochondria \[[@b33-ad-11-2-419], [@b42-ad-11-2-419]\]. Further, we discuss the LC3 reporter-mediated recognition of impaired mitochondria.

### Nix and BNIP3

Nix and BNIP3 are OMM proteins that interact with LC3 or its homologs through the LC3-interacting region (LIR) to form mitophagy receptors. BNIP3 and Nix are hypoxia-induced tail-anchored proteins that bind to the OMM via the carboxyl transmembrane domain. The N-terminal extends into the cytoplasm and is linked to LC3-related molecules\[[@b51-ad-11-2-419]-[@b53-ad-11-2-419]\]. BNIP3-dependent mitophagy requires drp1 to induce mitochondrial division. Inhibition of this process or drp1 knockout blocks hypoxia-induced mitophagy. Nix protein levels increase after erythrocyte maturation. Nix knockout inhibits the loss of the mitochondrial membrane potential and the isolation of mitochondrial autophagosomes. Nix-dependent mitophagy is induced by the loss of membrane potential caused by carbonyl cyanide m-chlorophenylhydrazone treatment. Therefore, Nix-mediated loss of membrane proteins is important in mitophagy \[[@b54-ad-11-2-419]\].

### FUNDC1

FUNDC1 is an OMM protein, which integrates with LC3 under hypoxia via its LIR structure. During starvation, mitophagy does not depend on FUNDC1; therefore, it specifically induces hypoxia \[[@b55-ad-11-2-419]\]. FUNDC1 is expressed under normoxic conditions; however, FUNDC1 and LC3 interact under hypoxic conditions upon dephosphorylation at Y18 \[[@b56-ad-11-2-419]\]. Furthermore, FUNDC1 is a mitochondrial receptor for unc-51-like autophagy activating kinase 1 (ULK1), which in turn is translocated to depolarized mitochondria and FUNDC1 phosphorylated at S17 and promotes mitophagy \[[@b56-ad-11-2-419]\]. Phosphoglycerate mutase family member 5 phosphatase is located at the mitochondria and dephosphorylates FUNDC1 at S13 under hypoxic conditions or upon treatment with carbonyl cyanide p-trifluoromethoxy phenylhydrazone. The latter promotes the interaction of the enzyme with LC3 and induces mitophagy \[[@b57-ad-11-2-419]\].

LC3 receptors BNIP3/Nix and FUNDC1 have been extensively characterized in cardiovascular studies. BCL2-like13 (Bcl2L13), autophagy/Beclin 1 regulator 1 (AMBRA1), and cardio phospholipids serve as LC3 receptors during mitophagy \[[@b16-ad-11-2-419], [@b42-ad-11-2-419], [@b58-ad-11-2-419]\]. They localize at the OMM thus eliminating the need for mitophagic receptors to mark the damaged mitochondria. Rather, they directly interact with LC3 via the LIR and identify and engulf the damaged mitochondria \[[@b42-ad-11-2-419], [@b48-ad-11-2-419], [@b50-ad-11-2-419]\].

Step 3. Mitochondrial phagocytic vesicles and lysosomes fuse into mitolysosomes
-------------------------------------------------------------------------------

Phagocytic vesicles fuse with damaged mitochondria to form mitolysosomes. Thereafter, various hydrolytic enzymes in the lysosome digest the damaged mitochondrial components, thereby executing the final step of mitophagy. Recent studies on mitophagy primarily focused on the formation, recognition, and interaction of phagocytic vesicles with damaged mitochondria. The detailed mechanism underlying the binding of phagocytic vesicles with lysosomes shall not be described in this review.

2.2 Research methods
--------------------

Discussed herein are several widely used techniques to assess mitophagy.

### Transmission electron microscopy (TEM)

The most prominent phenomenon in autophagy is the formation of a double-layered membrane around the cytosol and/or organelles. This structure fuses with the lysosome, its contents are released, and a single-layer membrane is formed. Therefore, early and late autophagy are easily distinguished by observing double- and single-membrane structures. Consistent with cell autophagy, early mitophagy potentially results in packaging of the double-membrane structure, which can be readily identified on the basis of its unique structure-mitochondrial crest. During late autophagy, mitochondria are transported to the lysosomes and can be identified from their density or residual structure. TEM is currently the best method to detect mitophagy. It is the \"gold standard\" method to directly detect autophagy \[[@b59-ad-11-2-419], [@b60-ad-11-2-419]\]. However, TEM has several limitations. Electron microscopy requires extensive sample preparation. Cell damage potentially resulting from human error interferes with observations. Moreover, mitochondrial structures are difficult to discern during later stages of autophagy. Therefore, this method has low sensitivity.

### Western blotting

A commonly used method to detect autophagy proteins is western blotting. Autophagy can be detected on the basis of the ratio of the LC3B II/I type marker protein and the extent of P62 degradation \[[@b61-ad-11-2-419]\]. Mitophagy is accompanied by the degradation of several mitochondrial proteins; hence, it may also be evaluated by measuring their levels. Mitochondrial degradation occurs through the autophagy pathway, and cytosolic LC3 protein is converted from type I to type II via conjugation with phosphatidylethanolamine. Therefore, LC3 detection is also a potential method of detecting autophagy. The use of autophagy inhibitors including Bafilomycin A1 (Baf A1) and hydroxychloroquine (HCQ) is also a prominent method of detecting autophagy \[[@b41-ad-11-2-419], [@b62-ad-11-2-419]\]. Recent studies have reported that the OMM, IMM, and matrix proteins are degraded via mitophagy, whereas certain proteins regulating mitochondrial division and migration are degraded by proteasomes or ATP-dependent protease pathways. TIM23, TOM20, Hsp60, and electron transport chain (ETC)-related proteins are commonly used as mitophagy markers \[[@b63-ad-11-2-419]\]. P62 can be recruited individually, since it is highly ubiquitinated after mitochondrial damage. P62 is involved in numerous signal transduction pathways and its function is complex. Therefore, the role of P62 in mitophagy detection is controversial \[[@b64-ad-11-2-419], [@b65-ad-11-2-419]\].

### Fluorescence labeling

GFP-LC3 is often used as an autophagosome marker. Following plasmid transfection, autophagosome formation may be assessed using a fluorescence microscope. Similarly, plasmids containing fluorescent markers or specific antibodies against certain mitochondrial proteins including TOM20 and cytochrome C can be used to label mitochondria. Several commercialized mitochondrial dyes such as MitoTracker and TMRE (Tetramethylrhodamine ethyl ester) are also potentially applicable. In general, mitochondria and autophagosomes/lysosomes can be labeled separately and the colocalization of mitochondria, autophagosomes, and lysosomes may be detected via confocal laser microscopy to detect mitophagy. LC3 fused with fluorescent proteins, such as GFP and RFP, helps observe mitochondrial incorporation into autophagosomes, accompanied with the extension of the isolation membrane through time-lapse microscopic imaging of live cells. GFP fluorescence is attenuated under acidic conditions; hence, GFP-LC3 does not label autolysosomes. However, RFP is resistant to the acidic environment of lysosomes. By harnessing the distinct properties of GFP and RFP, GFP-RFP-tandem tagging LC3 is a potentially useful tool to quantify mitophagy and helps distinguish autophagosomes and autolysosomes. However, this evaluation may overlook the previously reported mitophagy mediated via an LC3-independent mechanism \[[@b66-ad-11-2-419]-[@b68-ad-11-2-419]\]. Recently, a mitochondrial probe MitoTimer was developed, which is a red fluorescent protein Ds Red \"mutant\" and encodes a redox sensitive mitochondrial targeted protein that switches from green to red fluorescence upon oxidation \[[@b69-ad-11-2-419]\]. Therefore, MitoTimer is an ROS-dependent fluorophore. Furthermore, changes in the transition from green to red fluorescence are affected by temperature, oxygen, and light exposure; hence, this assay must be performed combinatorially with other methods to accurately determine the causes of changes in red or green fluorescence levels. Moreover, MitoTimer is a very useful tool to indirectly quantify mitophagy \[[@b70-ad-11-2-419]\]. This assay quantifies several pathophysiological parameters of mitochondria, accurately assesses their health status, and plays potentially important roles in future studies \[[@b62-ad-11-2-419], [@b71-ad-11-2-419], [@b72-ad-11-2-419]\]. Moreover, mitoKeima is also a fluorophore that can help quantify mitophagy. Changes in the emission wavelength of mitoKeima depend on the acidity (red color) or neutrality (green color) of the pH of the microenvironment, e.g., during the transfer from an autophagosome (green color) to a lysosome (red color). Hence, mitoKeima is a powerful pH-dependent fluorophore that is more specific for monitoring mitophagy than MitoTimer \[[@b73-ad-11-2-419], [@b74-ad-11-2-419]\].

### Determination of mitochondrial mass

Mitophagy is accompanied by a reduction in mitochondrial mass; therefore, direct detection of changes in mitochondrial mass helps detect mitophagy. Mitochondria are labeled with mitochondrial dyes or corresponding antibodies, and the number of mitochondria per cell is determined via flow cytometry. RT-PCR may be used to quantify mtDNA \[[@b75-ad-11-2-419]-[@b77-ad-11-2-419]\]. These methods directly quantify mitochondrial mass. Simultaneously, mitochondrial mass is regulated via numerous regulatory mechanisms, and mitochondrial biogenesis and degradation are reportedly two of the most prominent regulatory mechanisms. Therefore, the decline in mitochondrial mass may not only be affected by mitophagy but also a process involving multiple regulatory mechanisms. Hence, determination of mitochondrial mass is an adjunct method of detecting mitophagy \[[@b78-ad-11-2-419]\].

2.3 Factors inducing mitophagy
------------------------------

During cell growth and development, numerous endogenous or exogenous stimulants can alter the degree of mitophagy. Therefore, mitophagy is involved in various pathophysiological processes.

### Mitophagy and stress

In the cardiovascular system, mitophagy exerts protective effects in response to cellular starvation. Mitophagy is activated during starvation to regulate mitochondrial quality and quantity through elimination of damaged or redundant mitochondria. Mitophagy is enhanced during cellular hypoxia. Acetylcholine reduces the damage caused by hypoxia/reoxygenation by increasing mitophagy in H9C2 cells. Violent exercise alters mitophagy levels by adaptively regulating mitochondrial function \[[@b79-ad-11-2-419]-[@b81-ad-11-2-419]\].

### Mitophagy and the cellular defense

During intracellular pathogenic infections, mitophagy is induced to defend against pathogens. Pathogens also induce mitophagy and disrupt mitochondrial homeostasis. For example, sepsis induces reversible cardiac mitochondrial injury, and recovery is reportedly associated with mitophagy based on morphological and biochemical evidence, suggesting that mitophagy is activated and plays an important role during cardiac recovery from sepsis \[[@b82-ad-11-2-419], [@b83-ad-11-2-419]\].

### Mitophagy and the maintenance of cellular homeostasis

In normal cells, mitophagy may have a housekeeping function and renew mitochondrial components. Mitophagy participates in metabolic remodeling and is closely associated with inflammatory response factors. For example, orally administered polyaminospermine in mice enhances mitophagy, inhibits subclinical inflammation, and increases longevity. Changes in the degree of mitophagy modulate stem cell activity and chronic cardiomyocyte inflammation \[[@b19-ad-11-2-419], [@b84-ad-11-2-419]\].

### Mitophagy and the regulation of cell growth and development

Mitophagy alters the oxidative respiratory chain activity by regulating mitochondrial quantity and quality, thus contributing to the regulation of cell growth and development. For example, macrophage fibrosis factor (Mff)-deficient mice died of dilated cardiomyopathy at 13 weeks. Mitophagy was significantly elevated in their mutated tissues \[[@b84-ad-11-2-419], [@b85-ad-11-2-419]\].

### Mitophagy and aging

Cellular aging has a prominent mitochondrial basis. Mitophagy reportedly mediates various degenerative diseases and contributes to their pathophysiology and treatment. For example, mitophagy is disrupted in the heart of aged individuals and in senescent cells and DOX-treated hearts and cells \[[@b19-ad-11-2-419], [@b86-ad-11-2-419]\].

3. Mitophagy and cardiovascular disease
=======================================

Since mitophagy is involved in numerous prominent pathophysiological phenomena, it contributes to CVD pathogenesis.

3.1 Ischemic heart disease
--------------------------

Ischemic heart disease refers to myocardial damage caused by an imbalance between coronary blood flow and myocardial demand. Ischemic heart disease is a serious threat to human health. Ischemia causes myocardial cell injury and death \[[@b29-ad-11-2-419]\]. Modern therapies can restore coronary circulation and achieve reperfusion, thus potentially reducing cardiac damage. Nevertheless, the recovery of blood supply has an irreversible adverse effect known as ischemia/reperfusion (I/R) injury \[[@b87-ad-11-2-419], [@b88-ad-11-2-419]\]. As the energy-supplying organelles in cardiomyocytes, mitochondria are major targets of I/R injury. I/R induces the loss of mitochondrial cristae, reduces mitochondrial membrane potential, and opens the mitochondrial permeability transition pore (mPTP) \[[@b89-ad-11-2-419]\]. These effects lead to mitochondrial damage and an aggravation of the imbalance of mitophagy (excessive inhibition or promotion) \[[@b28-ad-11-2-419], [@b89-ad-11-2-419], [@b90-ad-11-2-419]\]. Mitophagy protects myocardial cells during I/R injury. I/R reduces mitophagy and stimulates apoptosis in cardiomyocytes \[[@b91-ad-11-2-419]\]. An appropriate increase in mitophagy potentially mitigates I/R injury-induced cardiomyocyte apoptosis. Simultaneously, however, mitophagy may also play a negative role in I/R injury. Inhibition of mitophagy potentially protects the myocardium against I/R injury, reduce cardiomyocyte apoptosis, improve cardiac function, and protect mitochondrial integrity\[[@b15-ad-11-2-419], [@b92-ad-11-2-419], [@b93-ad-11-2-419]\]. Key mitochondrial markers PINK1 and Parkin were reportedly upregulated and enhanced Parkin transfer and activation during I/R injury \[[@b94-ad-11-2-419]\]. I/R injury promotes BNIP3 upregulation and FUNDC1 downregulation \[[@b95-ad-11-2-419], [@b96-ad-11-2-419]\]. LC3 affinity for BNIP3 and FUNDC1 depends upon its phosphorylation levels. I/R injury potentially increases BNIP3 phosphorylation at S17, enhance the binding affinity of LC3, and elevate mitophagy. During I/R, phosphorylation at Y18 and S13 are increased, LC3 affinity decreased with a reduction in mitophagy \[[@b97-ad-11-2-419]-[@b99-ad-11-2-419]\].

3.2 Diabetic cardiomyopathy
---------------------------

Diabetic cardiomyopathy (DCM) is a major manifestation of organ damage in diabetic complications. DCM is an important cause of morbidity and mortality in individuals with diabetes. Mitochondrial dysfunction is a prominent contributor to diabetic cardiomyopathy \[[@b100-ad-11-2-419]\]. Mitochondria are the primary sources of ROS and targets for oxidative stress injury. In the diabetic myocardium, damaged mitochondria produce large amounts of ROS, which exacerbates mitochondrial damage and triggers a vicious cycle of cardiomyocyte death \[[@b101-ad-11-2-419]-[@b104-ad-11-2-419]\]. In individuals with diabetic cardiomyopathy and in animal and cellular models, impaired mitochondrial structure and function and increased ROS production have been commonly observed. In vivo analyses using animals revealed that antioxidant therapy protects against diabetic cardiomyopathy \[[@b105-ad-11-2-419]\]. However, clinical antioxidant therapy did not exert the same effect possibly because of the sustained release of ROS from damaged mitochondria \[[@b106-ad-11-2-419]\]. Blocking of continuous ROS synthesis via mitophagy is a potential key strategy to treat diabetic cardiomyopathy \[[@b102-ad-11-2-419], [@b106-ad-11-2-419]-[@b108-ad-11-2-419]\]. Nevertheless, the functional status and regulatory mechanisms of mitophagy in the diabetic myocardium are unknown. Mitophagy levels in a diabetic cardiomyopathy model were significantly different from those in the control. While cardiac mitophagy was inhibited in a type 1 diabetic mouse model, it was actually promoted in a type 2 diabetic mouse model \[[@b109-ad-11-2-419]-[@b113-ad-11-2-419]\]. It is yet unclear whether mitophagy protects against or induces injury in the pathogenesis of diabetic cardiomyopathy. Relative to the control, the contents of mitophagy-related proteins were significantly altered in several diabetic tissues including the heart. In male prediabetic rats, the generation of mitochondrial ROS increased and BNIP3 was downregulated in comparison with the corresponding values in the controls \[[@b14-ad-11-2-419], [@b114-ad-11-2-419]\]. In types 1 and 2 diabetes models, PINK1 and Parkin were downregulated \[[@b109-ad-11-2-419], [@b115-ad-11-2-419], [@b116-ad-11-2-419]\]. In the vascular smooth muscle cells of diabetic mice, PINK1 and Parkin were upregulated and mitophagy was induced relative to the control \[[@b117-ad-11-2-419]\].

3.3 Heart failure
-----------------

Heart failure (HF) is characterized by high morbidity and mortality and is the terminal stage in various heart diseases \[[@b118-ad-11-2-419], [@b119-ad-11-2-419]\]. Current methods of treating heart failure may mitigate or alleviate symptoms; however, the prognosis remains poor. To better determine treatment methods for heart failure, it is necessary to understand oxidative stress and chronic inflammation associated with this condition \[[@b119-ad-11-2-419]-[@b121-ad-11-2-419]\]. During heart failure, mitochondrial dysfunction is a common pathophysiological phenomenon, which has received increasing attention. Mitophagy is decreased with aging or disease \[[@b122-ad-11-2-419]\]. Consequently, elimination of damaged mitochondria is inadequate, ROS and peroxide levels are increased. Cardiomyocyte mitochondrial proteins, lipids, and DNA undergo oxidative damage and contribute to heart failure. These findings corroborate the clinical presentation of heart failure in aged patients and those with terminal heart disease \[[@b17-ad-11-2-419], [@b26-ad-11-2-419], [@b123-ad-11-2-419]\]. Biopsies of individuals with heart failure have revealed that the autophagy-specific genes beclin1 and LC3-II were downregulated after treatment \[[@b124-ad-11-2-419]\]. Therefore, we predicted that mitophagy is associated with the occurrence and development of heart failure. Mfn2 regulates heart failure-related mitophagy by altering the mitochondrial membrane potential \[[@b125-ad-11-2-419]\]. Subsequent experiments on heart failure models have revealed that insufficient mitophagy aggravates heart injury\[[@b122-ad-11-2-419]\]. PINK1 is generally downregulated in individuals with heart failure, indicating a reduction in mitophagy levels. However, it is uncertain whether PINK1 downregulation is the cause or effect of heart failure \[[@b126-ad-11-2-419], [@b127-ad-11-2-419]\]. In vivo studies using animals confirmed the role of PINK1 in heart failure. PINK1 knockout mice were more susceptible to overload-induced heart stress and consequent heart failure than wild type mice \[[@b128-ad-11-2-419]\]. Parkin-mediated mitophagy decreases with age \[[@b122-ad-11-2-419]\]. Moreover, the number of dysfunctional mitochondria increases with age until it surpasses the Parkin-mediated scavenging ability of mitophagy. With aging, myocardial mitophagy becomes inadequate to maintain the normal homeostatic of mitochondrial function. In mice, Parkin deficiency has resulted in the accumulation of dysfunctional cardiomyocyte mitochondria, which elevates the risk of heart failure after myocardial infarction \[[@b28-ad-11-2-419]\]. In mouse heart failure models induced via increased stress, Nix-silenced mice presented less myocardial fibrosis and more stable systolic function than wild type mice \[[@b129-ad-11-2-419]\]. Thus far, myocardial mitophagy has not been reportedly increased in individuals with heart failure. Nevertheless, an increase in mitophagy leads to excessive mitochondrial clearance, and the remaining mitochondria cannot accommodate the energy demand of cardiomyocytes. This situation is extremely unfavorable for individuals with heart failure

3.4 Hypertension
----------------

Hypertension is a systemic disease with a high incidence and is closely associated with cardiovascular, cerebrovascular, kidney, and other diseases \[[@b130-ad-11-2-419]\]. There is no direct evidence for the role of mitophagy in the pathophysiology of hypertension. Complications of hypertension such as atherosclerosis, myocardial I/R injury and hypertrophy, and heart failure are closely associated with cardiomyocyte and endothelial mitochondrial dysfunction \[[@b131-ad-11-2-419]\]. Insufficient energy supply, kinetic imbalance, oxidative damage, abnormal signal transduction, and mitochondrial dysfunction caused by genetic mutations are risk factors for hypertension \[[@b132-ad-11-2-419]-[@b134-ad-11-2-419]\]. Myocardial hypertrophy associated with hypertension reportedly altered cardiomyocyte phenotype, function, and energy metabolism. These changes were reflected in the utilization of metabolic substrates and the function of the ETC, ATP synthesis, and other processes \[[@b135-ad-11-2-419]\]. ROS regulate vascular structure and tension remodeling. An increase or retention of ROS may cause vasoconstriction, decrease vascular diastolic function, damage smooth muscle cells, promote vascular inflammation and remodeling, increase peripheral vascular resistance, and aggravate hypertension \[[@b136-ad-11-2-419]\]. Mfn1, Mfn2, and OPA1 (optic atrophy 1) mRNA levels, which are associated with mitochondrial dynamics, were decreased in hypertensive rat heart models. Hence, mitochondrial fragmentation is increased in hypertension \[[@b137-ad-11-2-419]\]. Mitochondrial division is a compensatory mechanism maintaining cardiac contraction in hypertension and exacerbating ventricular wall thickening \[[@b138-ad-11-2-419]\]. Hypertension is suggested to alter mitochondrial function, energy metabolism, and mitochondrial dynamics in cardiomyocytes \[[@b131-ad-11-2-419]\]. Clearance of mitochondrial dysfunction is closely associated with mitophagy. Therefore, elucidation of the role of mitophagy in the occurrence and development of hypertension may be important to investigate the pathophysiology of this condition and novel treatments for this condition.

3.5 Atherosclerosis
-------------------

Atherosclerosis (AS) is a chronic disease characterized by lipid accumulation, vascular smooth muscle cell proliferation, apoptosis, and local inflammation \[[@b139-ad-11-2-419]\]. The pathogenesis of atherosclerosis is complex and includes abnormal lipid metabolism, inflammation, endothelial injury, oxidative stress, and other mechanisms \[[@b140-ad-11-2-419], [@b141-ad-11-2-419]\]. In the pathophysiology of atherosclerosis, plaque tissue stability determines disease occurrence and progression \[[@b142-ad-11-2-419]\]. In plaque macrophages, vascular smooth muscle cells, and endothelial cells, mitophagy clears the damaged mitochondria, stabilizes the mitochondrial function in the damaged cells, reduces cell damage, maintains plaque integrity, and prevents disease progression caused by plaque tissue rupture \[[@b143-ad-11-2-419]\]. Oxidized low-density lipoprotein (ox-LDL) has been widely used to generate atherosclerosis models because it is an atherosclerotic agent. In vascular smooth muscle cells, ox-LDL disrupts mitochondrial structure, increases ROS levels, and induces mitochondrial dysfunction \[[@b144-ad-11-2-419]\]. Furthermore, Ox-LDL activates mitophagy, which eliminates nonfunctional and damaged mitochondria. After the addition of mitophagy inhibitors, mitophagy and its related pathway proteins are significantly decreased, and cell apoptosis is significantly increased \[[@b145-ad-11-2-419]\]. Mitophagy protects against atherosclerotic stress-induced apoptosis in human vascular smooth muscle cells (VSMCs) \[[@b146-ad-11-2-419]-[@b148-ad-11-2-419]\]. PINK1/Parkin was reportedly upregulated in atherosclerotic disease models than in normal tissues. PINK1 overexpression enhances the protective effect of mitophagy on VSMCs, whereas PINK1 gene knockout counteracts it \[[@b146-ad-11-2-419], [@b147-ad-11-2-419]\]. Hence, mitophagy is a potential target for the stabilization of atherosclerotic plaques.

3.6 Arrhythmia
--------------

Arrhythmia is a prominent aspect of CVD. It may occur individually or in association with other cardiovascular disease. In a healthy heart, coordinated electrical propagation supports cardiac function; upon failure of such a cardiac action potential, cardiac arrhythmia occurs \[[@b149-ad-11-2-419]\]. Although there is no direct evidence of the role of mitophagy in arrhythmia, extensive evidence indicates that mitochondria play a functional role in arrhythmia. Mitochondria are involved in arrhythmia owing to their ability to produce ATP and ROS \[[@b150-ad-11-2-419]\]. Mitochondrial dysfunction reduces ATP production, affects cardiac electrical conduction, thus altering sarcolemmal K^+^ fluxes via ATP-sensitive potassium channels \[[@b151-ad-11-2-419]\]. However, excessive mitochondrial ROS production can introduce heterogeneity in cardiac action potentials \[[@b152-ad-11-2-419]\]. Alterations in ATP and ROS levels are based on a vicious cycle: during mitochondrial dysfunction, the mitochondrial membrane potential reduced, thus decreasing ATP and increasing ROS levels; thereafter, further mitochondrial dysfunction is induced, with the mitochondrial membrane potential reduced, with a concomitant reduction in ATP generation. This vicious cycle causes electrophysiological alterations, thereby causing arrhythmia \[[@b150-ad-11-2-419], [@b153-ad-11-2-419]\]. Proper mitophagy can eliminate damaged mitochondria, maintain mitochondrial homeostasis in cells, and prevent damage to hazardous substances, thus further disrupting cellular phenomena. During arrhythmia, changes in ATP and ROS levels caused by mitochondrial damage play an important role in mitophagy. Therefore, we can boldly speculate that mitophagy eliminates damaged mitochondria and regulates ROS and ATP levels to a certain extent, thereby inhibiting or decelerating the occurrence of arrhythmia.

3.7 Stroke
----------

Stroke is an acute cerebrovascular disease, which can be categorized as ischemic stroke and hemorrhagic stroke in accordance with its pathogenesis. Ischemic stroke is caused by atherosclerotic plaque disruption and spontaneous intracranial hemorrhage and is often caused by hypertension \[[@b154-ad-11-2-419], [@b155-ad-11-2-419]\]. Current studies on stroke have revealed significant advancements; however, current treatments still have risks \[[@b156-ad-11-2-419]\]. In ischemic stroke, mitochondrial aggregation events that cause cell death and tissue infarction primarily result from a lack of nutrients and oxygen and reduction in ATP, and during the reperfusion phase, extensive cellular damage are caused by a mitochondrial Ca^2+^ overload, mPTP opening, and excessive production of ROS \[[@b157-ad-11-2-419], [@b158-ad-11-2-419]\]. In hemorrhagic stroke, mitochondrial dysfunction decreases mitochondrial respiratory function, and ischemia decreases oxygen metabolism in hematoma \[[@b159-ad-11-2-419]\]. Hence, the regulation of mitochondrial homeostasis is an apparently promising therapy for stroke, and mitophagy serves as an important underlying mechanism. However, mitophagy is a double-edged sword in stroke; there is no consensus regarding whether mitophagy plays a protective or damaging role in stroke. In in vivo and in vitro models of stroke, BNIP3 and Nix are reportedly upregulated, leading to delayed neuronal death \[[@b160-ad-11-2-419]\]; however, subsequent studies reported that Nix-mediated mitophagy protects against ischemic stroke \[[@b161-ad-11-2-419]\]. PINK1/Parkin-mediated mitophagy is activated in brain damage induced by ischemia stroke; however, the underlying function is unclear \[[@b162-ad-11-2-419]\]. Although the function of mitophagy is still unclear in stroke, it is generally accepted that the degree of mitophagy is the determinant during stroke, and physiological levels can be beneficial, while excessive or inadequate levels could be deleterious \[[@b30-ad-11-2-419], [@b163-ad-11-2-419]\].

###### 

Therapeutic application of mitophagy.

  Diseases                                    Representatives                     Mechanisms            Effects      References
  ------------------------------------------- ----------------------------------- --------------------- ------------ ----------------------------------------------
  MicroRNAs                                                                                                          
  I/R                                         MiR-410                             Mitophagy-            damage       \[[@b165-ad-11-2-419]\]
  I/R                                         MiR-137                             BNIP3/FUNDC1-         \-           \[[@b166-ad-11-2-419]\]
  Cardiac Lipotoxicity, DCM                   MiR-133a                            Nix-                  protection   \[[@b167-ad-11-2-419]\]
                                                                                                                     
  Clinical drugs and chemical reagents                                                                               
                                                                                                                     
  I/R                                         Melatonin                           PINK1/Parkin-         protection   \[[@b168-ad-11-2-419]\]
  DCM                                         Melatonin                           PINK1/Parkin+         protection   \[[@b169-ad-11-2-419]\]
  AS                                          Melatonin                           PINK1/Parkin+         protection   \[[@b170-ad-11-2-419]\]
  I/R                                         Simvastatin                         Parkin/P62+           protection   \[[@b171-ad-11-2-419]\]
  I/R                                         Liraglutide                         Parkin+               protection   \[[@b172-ad-11-2-419]\]
  I/R                                         Zine                                PINK1+                protection   \[[@b173-ad-11-2-419]\]
  I/R                                         Sevoflurane postconditioning        Parkin-               protection   \[[@b174-ad-11-2-419]\]
  I/R                                         TEMPOL preconditioning              PINK1/Parkin+         protection   \[[@b175-ad-11-2-419]\]
  HF                                          Curcumin                            BNIP3-                protection   \[[@b176-ad-11-2-419]\]
  Cardiotoxicity                              Ellagic acid                        BNIP3-                protection   \[[@b177-ad-11-2-419]\]
  Stroke                                      Tunicamycin and thapsigargin        Mitophagy+            protection   \[[@b178-ad-11-2-419]\]
  Stroke                                      Peroxynitrite                       PINK1/Parkin+         damage       \[[@b179-ad-11-2-419]\]
  Stroke                                      Naringin                            Parkin-               protection   \[[@b180-ad-11-2-419]\]
                                                                                                                     
  Signal pathways                                                                                                    
                                                                                                                     
  AS                                          NR4A1/CaMKII activation             Parkin+               damage       \[[@b145-ad-11-2-419]\]
  Stroke                                      MAPK-ERK-CREB blockade              Mfn2-                 damage       \[[@b181-ad-11-2-419]\]
  I/R                                         Rab5 endosomal pathway activation   Parkin+               protection   \[[@b182-ad-11-2-419]\].
  I/R                                         P53/TIGAR activation                BNIP3-                damage       \[[@b183-ad-11-2-419]\]
  HF                                          JNK/FOXO3a activation               BNIP3+                damage       \[[@b184-ad-11-2-419]\].
                                                                                                                     
  Activators/inhibitors, genes knock in/out                                                                          
                                                                                                                     
  I/R                                         STAT1 activation                    Mitophagy-            damage       \[[@b185-ad-11-2-419]\]
  AS                                          PINK1/Parkin knockout               PINK1/Parkin-         damage       \[[@b146-ad-11-2-419], [@b147-ad-11-2-419]\]
  I/R                                         GPER activation                     PINK1/Parkin-         protection   \[[@b93-ad-11-2-419]\]
  I/R                                         ALDH2 activation                    PINK1/Parkin-         protection   \[[@b186-ad-11-2-419]\]
  DCM                                         Sirt3 overexpression                Parkin+               protection   \[[@b187-ad-11-2-419]\]
  DCM                                         Mst1 knockout                       Parkin+               protection   \[[@b188-ad-11-2-419]\]
  HF                                          BAG3 knockdown                      Parkin-               damage       \[[@b189-ad-11-2-419]\]
  AS                                          F13A                                PINK1/Parkin-         protection   \[[@b190-ad-11-2-419]\]
  HF                                          CsA                                 PINK1/Parkin-         protection   \[[@b191-ad-11-2-419]\]
  HF                                          Akt2 knockout                       BNIP3/PINK1/Parkin+   protection   \[[@b192-ad-11-2-419]\]
  Stroke                                      Nix knockout                        Nix-                  damage       \[[@b161-ad-11-2-419]\]
  I/R                                         DUSP1 activation                    BNIP3-                protection   \[[@b98-ad-11-2-419]\]
  HF                                          SWI/SNF deletion                    BNIP3+                damage       \[[@b193-ad-11-2-419]\]
  I/R                                         FUNDC1 knockout                     FUNDC1-               damage       \[[@b96-ad-11-2-419]\]
                                                                                                                     
  Environmental stimuli                                                                                              
                                                                                                                     
  I/R                                         Mild hypothermia                    Parkin-               protection   \[[@b194-ad-11-2-419]\]
  I/R                                         Hypoxic preconditioning             FUNDC1+               protection   \[[@b96-ad-11-2-419]\]
  Myocardial inflammatory                     Acute exercise                      BNIP3+                protection   \[[@b80-ad-11-2-419]\]
  I/R                                         Exercise preconditioning            Parkin+               protection   \[[@b195-ad-11-2-419]\]
  Stroke                                      Acidic postconditioning             Mitophagy+            protection   \[[@b196-ad-11-2-419]\]
  Stroke                                      Remote ischemic post conditioning   Parkin+               protection   \[[@b197-ad-11-2-419]\]

4. Therapeutic application of mitophagy
=======================================

Mitophagy plays an important role in CVD pathogenesis and is, therefore, a potential therapeutic target. CVD can be treated, or its progress can be delayed by promoting or inhibiting mitophagy, thus maintaining the functional stability of mitochondria and reducing cell damage in the disease state ([Table 1](#T1-ad-11-2-419){ref-type="table"}).

4.1 MicroRNAs
-------------

MicroRNAs are small, single-stranded, noncoding RNA molecules which inhibit the translation of target mRNAs or induce their degradation \[[@b164-ad-11-2-419]\]. MiR-410 is reportedly significantly upregulated in an I/R injury model of human adult cardiomyocytes (HACMs), which presented decreased mitochondrial function and loss of mitophagy. MiR-410 overexpression reportedly decreased cell viability, ATP generation, mitochondrial membrane potential, and mitophagy. In contrast, miR-410 downregulation had the opposite effect. MiR-410 directly targeted HSPB1 and regulated its activity and mitophagy \[[@b165-ad-11-2-419]\]. MiR-137 is reportedly significantly upregulated under hypoxia, wherein it downregulates Nix and FUNDC1 and impairs mitophagy \[[@b166-ad-11-2-419]\]. In lipid toxicity and diabetic mouse models, miR-133a was reportedly downregulated and Nix was upregulated. MiR-133a upregulation inhibited Nix translation, regulated mitochondrial function, and stabilized mitochondrial membrane potential \[[@b167-ad-11-2-419]\].

4.2 Clinical drugs and chemical reagents
----------------------------------------

Certain drugs and chemicals regulate mitophagy. Melatonin prevents the opening of the mPTP and the activation of PINK1/Parkin in the microcirculating endothelial cells of an I/R mouse model. Melatonin prevents mitophagy-mediated cell death and protects cardiac microvessels from I/R injury; the underlying mechanism may be attributed to the inhibitory effects of melatonin on mitochondrial fission VDAC1 HK2 mPTP mitophagy axis via activation of AMPKα \[[@b168-ad-11-2-419]\]. Furthermore, melatonin restores mitophagy in diabetic cardiomyopathy probably via Parkin translocation and Mst1 repression \[[@b169-ad-11-2-419]\]. Subsequent studies reported that melatonin induced mitophagy through the Sirt3/FOXO3a/Parkin signaling pathway, attenuated NLRP3 (NLR family pyrin domain containing 3) inflammasome activation, and prevented the progression of atherosclerosis \[[@b170-ad-11-2-419]\]. Simvastatin suppresses mTOR signaling, triggers mitochondrial translocation of Parkin and p62/SQSTM1, activates mitophagy, and reduces the infarct area in mouse and HL-1 cell models of myocardial infarction. Coenzyme Q may influence the anti-ischemic effect of statins by interfering with mitophagy \[[@b171-ad-11-2-419]\]. Liraglutide upregulated SIRT1 and Parkin, activated mitophagy, reduced cellular oxidative stress, balanced the redox reaction, and maintained mitochondrial homeostasis. These effects promoted myocardial repair after myocardial infarction \[[@b172-ad-11-2-419]\]. In both healthy and I/R rat cardiomyocytes, zinc (Zn) upregulated PINK1 and Beclin1, activated mitophagy, inhibited the generation of superoxide mitochondria, reduced the loss of mitochondrial membrane potential during reperfusion, prevented mitochondrial oxidative stress, and protected heart damage \[[@b173-ad-11-2-419]\]. Sevoflurane posttreatment downregulated Parkin in a rat I/R model, inhibited mitophagy, maintained ATP, reversed mitochondrial damage, and protected the heart \[[@b174-ad-11-2-419]\]. Pretreatment with the antioxidant TEMPOL upregulated PINK1 and Parkin, restored mitophagy in the aged myocardium upon isoproterenol (ISO) treatment, and promoted cardiac recovery in aging animals \[[@b175-ad-11-2-419]\]. BNIP3 binding activated acetyltransferase p300 and increased histone acetylation and transcription factor GATA4 levels. Curcumin inhibited these phenomena and reduced mitophagy levels \[[@b176-ad-11-2-419]\]. Erythorbic acid (EA) reduced mitochondrial injury and necrotic cell death of cardiac myocytes and alleviated oxidative damage and cardiac dysfunction during anthracycline therapy by functionally abrogating Bnip3 activity, thus inhibiting BNIP3-induced mitophagy \[[@b177-ad-11-2-419]\]. Tunicamycin and thapsigargin-induced ER stress protects against ischemic stroke injury, which is probably involved in mitophagy induction \[[@b178-ad-11-2-419]\]. Peroxynitrite-induced PINK1/Parkin-mediated mitophagy activation through drp1 recruitment to damaged mitochondria aggravates cerebral I/R injury during stroke \[[@b179-ad-11-2-419]\]. A natural antioxidant naringin potentially inhibits peroxynitrite-mediated mitophagy activation by inhibiting the translocation of Parkin to the mitochondria and attenuating ischemic stroke injury \[[@b180-ad-11-2-419]\].

4.3 Signaling pathways
----------------------

Several signaling pathways regulate molecules that control mitophagy. In a mouse atherosclerosis model established with ox-LDL, NR4A1 was significantly upregulated and controlled Parkin activation through posttranscriptional CaMKII modification. Thus, it activated Parkin-mediated mitophagy. Excessive mitophagy reduced mitochondrial quality which, in turn, caused energy shortage and mitochondrial dysfunction \[[@b145-ad-11-2-419]\]. Furthermore, blockade of the MAPK-ERK-CREB signaling pathway upregulated NR4A1 and repressed Mfn2-mediated mitophagy, thus expanding the area of cerebral infarction and increasing neuronal apoptosis \[[@b181-ad-11-2-419]\]. In cardiomyocytes, damaged mitochondria are sequestered in rab5-positive early endosomes via the ESCRT mechanism, which depends on Parkin, and the loss of rab5 function increases the susceptibility of embryonic fibroblasts and cardiomyocytes to cell death \[[@b182-ad-11-2-419]\]. In a mouse ischemic model, activation of the p53-TIGAR axis downregulated BNIP3, inhibited mitophagy, caused the accumulation of damaged mitochondria, and weakened the cardioprotective effect \[[@b183-ad-11-2-419]\]. The JNK signaling pathway is a key regulator of the FOXO3a transcription factor, which promotes BNIP3 expression in heart failure models. JNK influences the degree of mitophagy by regulating the level of BNIP3\[[@b184-ad-11-2-419]\].

4.4 Activators/inhibitors and gene knock in/out
-----------------------------------------------

Certain receptor antagonists, inhibitors of upstream molecules, and gene knockouts directly or indirectly regulate mitophagy. STAT1 is not only localized in the mitochondria but also serves as an LC3b binding partner; hence, STAT1 decreases mitophagy and promotes cell death in the myocardial I/R response \[[@b185-ad-11-2-419]\]. Silencing of PINK1 and Parkin reduced mitophagy in atherosclerosis and enhanced apoptosis in VSMCs via ox-LDL. In contrast, PINK1 and Parkin overexpression inhibited cell death \[[@b146-ad-11-2-419], [@b147-ad-11-2-419]\]. G protein-coupled estrogen receptor 1 (GPER) agonist increases GPER activity, reduces Parkin translocation from the cytosol to the mitochondria, and downregulates PINK1 protein expression, inhibiting the PINK1/Parkin pathway and mitophagy, protecting mitochondrial structural integrity and function, and protecting the heart after I/R injury \[[@b93-ad-11-2-419]\]. Both in I/R rats and hypoxia/reoxygenation H9C2 cells, ALDH2 activation suppressed phosphatase and PINK1/Parkin expression, preventing 4-hydroxynonenal, ROS, and mitochondrial superoxide accumulation, and regulating mitophagy, thus protecting the heart against I/R injury \[[@b186-ad-11-2-419]\]. In a mouse model of diabetic cardiomyopathy, Sirt3 overexpression activated deacetylation of Foxo3A and expression of Parkin, upregulated Parkin-dependent mitophagy, inhibited mitochondrial damage and apoptosis in cardiomyocytes, and played an important role in the occurrence and development of diabetic cardiomyopathy \[[@b187-ad-11-2-419]\]. Mst1 knockout reportedly significantly upregulated Parkin, enhanced mitochondrial translocation, and protected the myocardium of diabetic mice. These effects may be associated with Sirt3 downregulation via Mst1 \[[@b188-ad-11-2-419]\]. BAG3 functions upstream of Parkin, and BAG3 knock-down reduced PINK1/Parkin-mediated mitophagy and impaired the clearance of defective mitochondria, thus increasing levels of toxicity within the cells and subsequent cell death in the context of heart failure \[[@b189-ad-11-2-419]\]. In AS, apelin-13 increases mitophagy by activating the PINK1/Parkin pathway, and F13A is an apelin-13 antagonist in PINK1 and Parkin-dependent mitophagy, which blocks the effect of apelin-13 in the progression of atherosclerosis \[[@b190-ad-11-2-419]\]. Both CsA and PINK1 knockout significantly downregulated PINK1 and Parkin proteins in senescent cardiomyocytes, thus reducing the level of mitophagy and blocking cardiomyocyte senescence \[[@b191-ad-11-2-419]\]. Akt2 knockout prevented cardiac aging by upregulating Foxo1-related BNIP3, PINK1, and Parkin and by maintaining mitochondrial integrity \[[@b192-ad-11-2-419]\]. Nix knockout impaired mitophagy and aggravated ischemic stroke in mice, which can be rescued via Nix overexpression \[[@b161-ad-11-2-419]\]. DUSP1 overexpression inhibited BNIP3 activation, thereby inactivating the JNK pathway and alleviating mitophagy. This mechanism improved the survival of myocardial tissue after I/R\[[@b98-ad-11-2-419]\]. After SWI/SNF was deleted in Brg1/Brm double-mutant mice, BNIP3 was upregulated and mitophagy was increased. Consequently, small and fragmented mitochondria were formed. This reaction corresponded with changes occurring during heart failure\[[@b193-ad-11-2-419]\]. In the I/R model of FUNDC1 knockout mice, mitophagy was inhibited and cardiac injury was aggravated \[[@b96-ad-11-2-419]\].

4.5 Environmental stimuli
-------------------------

Certain environmental stimuli can inhibit or promote mitophagy and alter the content of the proteins related to this phenomenon. Mild hypothermia downregulated Parkin in hippocampal neurons in a cardiac arrest model, diminishing mitophagy in the neurons, protecting mitochondria, and improving neurological function after cardiac arrest \[[@b194-ad-11-2-419]\]. Hypoxic preconditioning induced FUNDC1-dependent activation of mitophagy and decreased I/R-induced cardiac injury \[[@b96-ad-11-2-419]\]. Myocardial mitochondrial function adapts to stress during acute exercise and manifests as significant upregulation of the mitophagy-related protein BNIP3, which stimulates mitophagy and minimizes myocardial injury \[[@b80-ad-11-2-419]\]. Simultaneously, exercise preconditioning significantly suppresses exhaustive exercise-induced hypoxia-ischemia injuries through upregulated parkin-dependent mitophagy \[[@b195-ad-11-2-419]\]. Acidic postconditioning-induced mitophagy renders the brain resistant to ischemic stroke through recruitment of PARK2 to mitochondria \[[@b196-ad-11-2-419]\]. Remote ischemic post-conditioning promoted mitophagy via Parkin upregulation and inhibited oxidative stress responses, thus mitigating cerebral I/R injury in a rat model of stroke \[[@b197-ad-11-2-419]\].

Figure 2.The graphical abstract. Mitophagy plays an important role in cardiovascular disease, and the degree of mitophagy can be detected via TEM, western blotting, fluorescence labeling, and mitochondrial mass determination, and the related molecular mechanism depends on PINK1/Parkin, CHDH, Nix/BNIP3, FUNDC1, etc. Mitophagy is related with certain physiological and pathological phenomena including stress, cellular defense, maintenance of cellular homeostasis, regulation of cell growth and development, and aging; these phenomena are also involved in the pathogenesis of cardiovascular diseases including ischemic heart disease, diabetic cardiomyopathy, heart failure, hypertension, atherosclerosis, arrhythmia, and stroke, and these diseases are closely associated with mitophagy. Therefore, certain factors including microRNAs, clinical drugs and chemical reagents, signaling pathways, activators/inhibitors and gene knock in/out, and environmental stimuli can regulate the level of mitophagy to alter the progression of these diseases.

5. Conclusion and Outlook
=========================

Mitochondrial injury and dysfunction are prominent pathophysiological mechanisms of CVD. Mitophagy potentially mitigates or alleviates these disorders and maintains cellular stability. The underlying mechanisms are complex, interrelated, and regulated by numerous stimulating factors. Several factors induce mitophagy during cellular growth, development, aging, and death. Alterations in the degree of mitophagy may alter the course of cardiovascular disease. Therefore, mitophagy is a potential therapeutic target for cardiovascular disease ([Fig. 2](#F2-ad-11-2-419){ref-type="fig"}). Nevertheless, it is yet unclear whether mitophagy retards or accelerates damage in CVD pathogenesis. Furthermore, it is unclear whether mitophagy is mediated by the unique functions of different molecules. Further studies are required to investigate whether the mechanisms underlying mitophagy induced by various molecules have mutual effects and the role of mitophagy in CVD, thus leading to advancements in the development of clinical diagnoses and treatments.
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